AAOpt 2025: Advances in regenerative medicine for the ocular surface | Optometry Times - Clinical News

LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced preliminary net sales results for the third quarter ended September 26, 2025. The company reported preliminary net sales of $94.7 million, up 6.9 percent compared with $88.6 million in the same